Botulinum toxin in multiple sclerosis.
Local administration of botulinum toxin (BoTx) inhibits presynaptic acetylcholine release. All cholinergically innervated muscles and glands can be paralyzed accordingly. Studies on the application of BoTx in multiple sclerosis have shown good results for focal spasticity, in particular, of the extremities. The first promising data were published on bladder disorders, especially with regard to detrusor sphincter dyssynergia and detrusor hyperreflexia. Hyperhidrosis, hypersalivation and proctologic symptoms might be other areas of application. Approval, however, has been greatly restricted which limits the therapeutic range of use.
Jost
Wolfgang H
WH
Dept. of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191, Wiesbaden, Germany. jost.neuro@dkd-wiesbaden.de
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D001745:Urinary Bladder Diseases / Q000188:drug therapy / Q000209:etiology
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A